186 related articles for article (PubMed ID: 34626221)
41. Immunohistochemical distinction of endometrial stromal sarcoma and cellular leiomyoma.
Agoff SN; Grieco VS; Garcia R; Gown AM
Appl Immunohistochem Mol Morphol; 2001 Jun; 9(2):164-9. PubMed ID: 11396634
[TBL] [Abstract][Full Text] [Related]
42. Med12 gain-of-function mutation causes leiomyomas and genomic instability.
Mittal P; Shin YH; Yatsenko SA; Castro CA; Surti U; Rajkovic A
J Clin Invest; 2015 Aug; 125(8):3280-4. PubMed ID: 26193636
[TBL] [Abstract][Full Text] [Related]
43. Genetic heterogeneity in leiomyomas of deep soft tissue.
Panagopoulos I; Gorunova L; Brunetti M; Agostini A; Andersen HK; Lobmaier I; Bjerkehagen B; Heim S
Oncotarget; 2017 Jul; 8(30):48769-48781. PubMed ID: 28591699
[TBL] [Abstract][Full Text] [Related]
44. Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation.
Corachán A; Trejo MG; Carbajo-García MC; Monleón J; Escrig J; Faus A; Pellicer A; Cervelló I; Ferrero H
Fertil Steril; 2021 Feb; 115(2):512-521. PubMed ID: 33036796
[TBL] [Abstract][Full Text] [Related]
45. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases.
Chu PG; Arber DA; Weiss LM; Chang KL
Mod Pathol; 2001 May; 14(5):465-71. PubMed ID: 11353058
[TBL] [Abstract][Full Text] [Related]
46. MED12 mutation frequency in unselected sporadic uterine leiomyomas.
Heinonen HR; Sarvilinna NS; Sjöberg J; Kämpjärvi K; Pitkänen E; Vahteristo P; Mäkinen N; Aaltonen LA
Fertil Steril; 2014 Oct; 102(4):1137-42. PubMed ID: 25108465
[TBL] [Abstract][Full Text] [Related]
47.
Heikkinen T; Äyräväinen A; Hänninen J; Ahvenainen T; Bützow R; Pasanen A; Vahteristo P
Hum Reprod Open; 2018; 2018(4):hoy020. PubMed ID: 30895261
[TBL] [Abstract][Full Text] [Related]
48. A mediator complex subunit 12 gain-of-function mutation induces partial leiomyoma cell properties in human uterine smooth muscle cells.
Takao T; Ono M; Yoshimasa Y; Masuda H; Maruyama T
F S Sci; 2022 Aug; 3(3):288-298. PubMed ID: 35643626
[TBL] [Abstract][Full Text] [Related]
49. Use of oxytocin receptor expression in distinguishing between uterine smooth muscle tumors and endometrial stromal sarcoma.
Loddenkemper C; Mechsner S; Foss HD; Dallenbach FE; Anagnostopoulos I; Ebert AD; Stein H
Am J Surg Pathol; 2003 Nov; 27(11):1458-62. PubMed ID: 14576480
[TBL] [Abstract][Full Text] [Related]
50. MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.
Kämpjärvi K; Mäkinen N; Mehine M; Välipakka S; Uimari O; Pitkänen E; Heinonen HR; Heikkinen T; Tolvanen J; Ahtikoski A; Frizzell N; Sarvilinna N; Sjöberg J; Bützow R; Aaltonen LA; Vahteristo P
Br J Cancer; 2016 Jun; 114(12):1405-11. PubMed ID: 27187686
[TBL] [Abstract][Full Text] [Related]
51. Cell cultures in uterine leiomyomas: rapid disappearance of cells carrying MED12 mutations.
Nadine Markowski D; Tadayyon M; Bartnitzke S; Belge G; Maria Helmke B; Bullerdiek J
Genes Chromosomes Cancer; 2014 Apr; 53(4):317-23. PubMed ID: 24446130
[TBL] [Abstract][Full Text] [Related]
52. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity.
de Graaff MA; Cleton-Jansen AM; Szuhai K; Bovée JV
Hum Pathol; 2013 Aug; 44(8):1597-604. PubMed ID: 23517922
[TBL] [Abstract][Full Text] [Related]
53. Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.
Kämpjärvi K; Kim NH; Keskitalo S; Clark AD; von Nandelstadh P; Turunen M; Heikkinen T; Park MJ; Mäkinen N; Kivinummi K; Lintula S; Hotakainen K; Nevanlinna H; Hokland P; Böhling T; Bützow R; Böhm J; Mecklin JP; Järvinen H; Kontro M; Visakorpi T; Taipale J; Varjosalo M; Boyer TG; Vahteristo P
Prostate; 2016 Jan; 76(1):22-31. PubMed ID: 26383637
[TBL] [Abstract][Full Text] [Related]
54. Intravenous leiomyomatosis: molecular analysis of 17 cases.
Lu B; Liu Q; Tang L; Ma Y; Shi H
Pathology; 2020 Feb; 52(2):213-217. PubMed ID: 31889549
[TBL] [Abstract][Full Text] [Related]
55. Fusion of HMGA2 to COG5 in uterine leiomyoma.
Velagaleti GV; Tonk VS; Hakim NM; Wang X; Zhang H; Erickson-Johnson MR; Medeiros F; Oliveira AM
Cancer Genet Cytogenet; 2010 Oct; 202(1):11-6. PubMed ID: 20804914
[TBL] [Abstract][Full Text] [Related]
56. [Mesenchymal uterine tumors. Leiomyomas].
Lax S
Pathologe; 2009 Jul; 30(4):274-83. PubMed ID: 19495761
[TBL] [Abstract][Full Text] [Related]
57. Use of histone deacetylase 8 (HDAC8), a new marker of smooth muscle differentiation, in the classification of mesenchymal tumors of the uterus.
de Leval L; Waltregny D; Boniver J; Young RH; Castronovo V; Oliva E
Am J Surg Pathol; 2006 Mar; 30(3):319-27. PubMed ID: 16538051
[TBL] [Abstract][Full Text] [Related]
58. Comprehensive screening for MED12 mutations in gynaecological mesenchymal tumours identified morphologically distinctive mixed epithelial and stromal tumours.
Yuan CT; Huang WC; Lee CH; Lin MC; Lee CH; Kao YC; Huang HY; Kuo KT; Lee JC
Histopathology; 2017 May; 70(6):954-965. PubMed ID: 28002623
[TBL] [Abstract][Full Text] [Related]
59. Uterine cellular leiomyomata with chromosome 1p deletions represent a distinct entity.
Hodge JC; Pearce KE; Clayton AC; Taran FA; Stewart EA
Am J Obstet Gynecol; 2014 Jun; 210(6):572.e1-7. PubMed ID: 24412114
[TBL] [Abstract][Full Text] [Related]
60. Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity.
Turunen M; Spaeth JM; Keskitalo S; Park MJ; Kivioja T; Clark AD; Mäkinen N; Gao F; Palin K; Nurkkala H; Vähärautio A; Aavikko M; Kämpjärvi K; Vahteristo P; Kim CA; Aaltonen LA; Varjosalo M; Taipale J; Boyer TG
Cell Rep; 2014 May; 7(3):654-60. PubMed ID: 24746821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
